Targeting CB2 receptors and the endocannabinoid system for the treatment of pain 28 May Dr D Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans. Is lipid signaling through cannabinoid 2 receptors part of a protective system?